Oncotelic launches PDAOAI platform and opens TGF-β corpus access

Oncotelic Therapeutics, Inc.

Launched PDAOAI, an evidence-interrogation platform for extracting biological signals from large datasets without training custom LLMs.
Providing open access to a TGF-β literature corpus of over 125,000 PubMed abstracts via a dedicated Discord research channel.
Platform aims to enable researchers to analyze complex biomedical data without proprietary data training.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.